arrow
A

Argiris Symeonidis

university of patras
H指数:46
被引数:9,107

个人简介

暂无内容

教育背景

暂无内容

工作经历

暂无内容

荣誉奖项

暂无内容

RNA and Mitochondrial Reprogramming Associated with Azacytidine Treatment in Higher-Risk Myelodysplastic Syndromes: A Pilot Study

RNA和线粒体重编程与高危及骨髓增生异常综合征中阿扎胞苷治疗的关系:一项初步研究

Cancers
IF4.4
2026-08-180
OAAI
BRIDGE (OP-107): A Phase 2 Pharmacokinetic Study of Melflufen Plus Dexamethasone in Patients with Relapsed/Refractory Multiple Myeloma and Impaired Renal Function

BRIDGE (OP-107):美法仑肽联合地塞米松治疗肾功能受损的复发/难治性多发性骨髓瘤患者的2期药代动力学研究

2026-04-300
OAAI
Clinical outcomes of patients with lower risk myelodysplastic syndrome from EUMDS registry eligible for transplantation: Implications for transplantation strategies

低危骨髓增生异常综合征患者移植适应症的EUMDS登记临床结局:对移植策略的启示

2026-02-010
PRE
Infections in lower-risk myelodysplastic syndromes-prevalence and risk factors: a report from the European MDS Registry

低危骨髓增生异常综合征中的感染:患病率及危险因素——欧洲MDS登记研究报道

2025-10-011
OAAI
Lenalidomide Efficacy in Patients with MDS and Del-5q: Real-World Data from the Hellenic (Greek) National Myelodysplastic & Hypoplastic Syndromes Registry (EAKMYS)

来那度胺在伴del-5q的骨髓增生异常综合征患者中的疗效:来自希腊骨髓增生异常与低增生性综合征登记研究(EAKMYS)的真实世界数据

CANCERS
IF4.4
2025-04-220
OA
The seasonal distribution of immune thrombotic thrombocytopenic purpura is influenced by geography: Epidemiologic findings from a multi-center analysis of 719 disease episodes
2024-08-131
OAAI
Ixazomib plus daratumumab and dexamethasone: Final analysis of a phase 2 study among patients with relapsed/refractory multiple myeloma
2024-06-100
OAAI
Efficacy and safety of daratumumab with ixazomib and dexamethasone in lenalidomide-exposed patients after one prior line of therapy: Final results of the phase 2 study DARIA
2024-01-313
OAAI
PET for Response Assessment to R-da-EPOCH in Primary Mediastinal Large B-cell lymphoma: Who Is Worthy to be Irradiated?
2023-11-012
OAAI